Privacy Policy

We value your privacy. We will never give, sell, lease or otherwise disclose your personal information, unless required by law. Any information you give to ACSMA will be held securely, and only be used in ways you have agreed to. If you have any questions about this privacy policy please email us.

Resale or disclosure of information to third parties

ACSMA does not give, sell, lease any personal information collected at our site, including via website submission forms and newsletter sign up forms.

Browser information collected on the web site

ACSMA analyzes the web site logs to improve the value of the materials available on the web site. These web site logs are not personally identifiable, and ACSMA makes no attempt to link them with the individuals that actually browse the site.

Privacy of our e-newsletter email list

You must specifically opt-in to join our e-newsletter & email mailing lists using the forms provided on this web site. We do not give, sell or lease the addresses on our list to anyone.

Unsubscribe Policy

We only want to send our e-newsletter to those who would like to receive it. If you don’t want to receive any future emails from us, click on the one-click unsubscribe link at the bottom of each email.

Comments are closed.

Sign the pledge to support our campaign. Improve the lives of thousands of patients

Click here and give us your support to help us make the case for change. Together, we will make this happen.

Download the latest newsletter

Click here to view all ACSMA newsletters and download your selected edition(s).

Latest News

December 2016: ACSMA Campaign Update

read more

NICE Quality Standard recommend.......

read more

reply | retweet | favourite | 09:43 pm Feb 10

We have new case studies on the @ACSMA_UK website showcasing NHS self-monitoring excellence. #warfarin
reply | retweet | favourite | 06:01 pm Jan 12

Anticoagulation Therapy Services National Summit, 28 April 2017, London. See here for more info:
reply | retweet | favourite | 05:27 pm Jan 12

follow us on Twitter